These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 31813872)
1. Possibility of extending biopharmaceutics classification system based biowaiver to BCS class IIa drug. Khalid F; Hassan SMF; Noor R; Zaheer K; Hassan F Pak J Pharm Sci; 2019 Sep; 32(5):2065-2073. PubMed ID: 31813872 [TBL] [Abstract][Full Text] [Related]
2. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Jantratid E; Prakongpan S; Amidon GL; Dressman JB Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285 [TBL] [Abstract][Full Text] [Related]
3. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122 [TBL] [Abstract][Full Text] [Related]
4. Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole. Charoo N; Cristofoletti R; Graham A; Lartey P; Abrahamsson B; Groot DW; Kopp S; Langguth P; Polli J; Shah VP; Dressman J J Pharm Sci; 2014 Dec; 103(12):3843-3858. PubMed ID: 25312492 [TBL] [Abstract][Full Text] [Related]
8. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948 [TBL] [Abstract][Full Text] [Related]
9. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements. Davit BM; Kanfer I; Tsang YC; Cardot JM AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914 [TBL] [Abstract][Full Text] [Related]
12. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs. Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210 [TBL] [Abstract][Full Text] [Related]
13. Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help. Wu F; Cristofoletti R; Zhao L; Rostami-Hodjegan A Biopharm Drug Dispos; 2021 Apr; 42(4):118-127. PubMed ID: 33759204 [TBL] [Abstract][Full Text] [Related]
14. Biowaiver Monograph for Immediate-Release Dosage Forms: Levamisole Hydrochloride. Kambayashi A; de Meijer M; Wegman K; van Veldhuizen C; Abrahamsson B; Cristofoletti R; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Dressman J J Pharm Sci; 2023 Mar; 112(3):634-639. PubMed ID: 36563854 [TBL] [Abstract][Full Text] [Related]
16. Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations. Ono A; Sugano K Eur J Pharm Sci; 2014 Nov; 64():37-43. PubMed ID: 25151946 [TBL] [Abstract][Full Text] [Related]
17. Effect of the Similarity of Formulations and Excipients of Approved Generic Drug Products on In Vivo Bioequivalence for Putative Biopharmaceutics Classification System Class III Drugs. Ren P; Chan T; Yang WC; Frost M; Wang Y; Luke M; Kim MJ; Lionberger R; Zhang Y Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765334 [TBL] [Abstract][Full Text] [Related]